发明名称 |
COMPOUNDS |
摘要 |
A conjugate compound comprises a cell-specific portion, such as an antibody specific to tumour cell antigens, and an enzymatically active portion which will cleave a cyanogenic compound to release cyanide. Enzymes such as beta -glucosidases are suitable. The cyanogenic compound, e.g. amigdalin or some other plant-derived saccharide, is administered after the conjugate. Intravesical (intra-bladder) administration is preferred (for bladder cancers) and forms a further aspect of the invention, whether the compound is cyanide-liberating (as above) or suitable for therapy or imaging in any other way. |
申请公布号 |
WO9111201(A2) |
申请公布日期 |
1991.08.08 |
申请号 |
WO1991GB00104 |
申请日期 |
1991.01.24 |
申请人 |
IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED |
发明人 |
EPENETOS, AGAMEMNON, ANTONIOU;ROWLINSON-BUSZA, GAIL |
分类号 |
A61K39/395;A61K9/00;A61K31/7032;A61K45/00;A61K47/48;A61P35/00;A61P43/00 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|